三生國健(688336.SH):雙特異抗體SSGJ-706獲得FDA批准進入臨牀I-II期
格隆匯10月18日丨三生國健(688336.SH)公佈,近日,公司開展的一項臨牀試驗,“An Open-Label, Multi-Center, Phase I/II Study toEvaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Efficacy ofSSGJ-706 in Subjects with Advanced Solid Tumors, Relapsed or RefractoryLymphomas”(《一項在晚期實體瘤、復發或難治淋巴瘤受試者中評估SSGJ-706的安全性、耐受性、藥代動力學和初步療效的開放性、多中心、I/II期研究》)獲得美國食品藥品管理局同意進入I/II期臨牀研究。
SSGJ-706是三生國健利用自主知識產權(雙特異抗體平台)開發的一種重組雙特異抗體。該抗體同時結合PD1和另一個與腫瘤免疫抑制功能密切相關的靶點,從而更有效地促進T細胞活化和增殖,進一步增強其腫瘤殺傷活性。SSGJ-706的成功開發有望使更多的腫瘤患者從創新免疫療法中獲益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.